Although reovirus has been used in tests as a potential cancer therapeutic agent against a variety of cancer cells, its application to hepatocellular carcinoma cells, in which the hepatitis B virus (HBV) X (HBX) protein of HBV plays a primary role, has not yet been explored. Here, we describe experiments in which we use reovirus to treat Chang liver carcinoma cells expressing either a vector only (Chang-vec) or a vector encoding HBX protein (Chang-HBX). Although Chang-vec cells readily support reoviral proliferation and undergo apoptosis, Chang-HBX cells are highly resistant to reoviral infection and virus-induced apoptosis, even though HBX protein induces activation of Ras and inactivation of PKR, which are normally thought to enhance reoviral oncolysis. The resistance of Chang-HBX cells to reovirus may instead be explained by HBX-induced downregulation of death receptor 5 and activation of Stat1. Phosphorylated Stat1 activates interferon (IFN)-stimulated regulatory element (ISRE)-and IFN-g-activated sequence (GAS)-mediated transcription, leading to the production of IFN-b, whereas the reduced expression of Stat1 with its siRNA results in a decrease in IFN-b production, by which Chang-HBX cells eventually succumb to reovirus infection. This result further indicates that HBX induces the establishment of an antiviral state through Stat1 activation. Thus, it appears that active Ras does not override the antiviral effect mediated by the activation of Stat1. Accordingly, we report that HBX, an oncoprotein of HBV, can prevent reoviral oncolysis of hepatocellular carcinoma. This suggests there may be limits to the practical application of reovirus in the treatment of human cancers already expressing other oncoviral proteins.
Introduction
The human reovirus is a ubiquitous, non-enveloped virus with 10 segments of double-stranded RNA. 1, 2 The virus infection is usually restricted to the upper respiratory and gastrointestinal tracts and is often asymptomatic. [2] [3] [4] However, reovirus shows dramatic cytolytic activity in certain types of transformed cells. 5, 6 Good evidence that Ras-transformed cells are preferentially susceptible to reovirus (type 3 Dearing strain) through inactivation of PKR (dsRNA-activated protein kinase) phosphorylation has been reported, 7, 8 and activation of the oncogenic Ras signaling pathway enhances reoviral oncolytic targeting in various types of human cancers. 9, 10 Reoviral efficacy has been examined in the treatment of gliomas and other cancers in immunocompetent hosts and has not produced significant toxicities. 11 These and many other results have led to the current tests of reovirus in several clinical trials. 10, 12, 13 It has also been reported that reoviral oncolysis is associated with the induction of apoptosis in various cancer types.
14 Further investigation has revealed that tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL), a member of the TNF superfamily, is involved in reovirus-induced apoptosis. 15 Caspase 8, JNK and MAPK proteins also participate in apoptotic signaling following reoviral infection. 16 Human hepatitis B virus (HBV) induces acute and chronic hepatitis and is closely associated with the incidence of human liver cancer. 17 Among the four proteins that derive from the HBV genome, HBV X (HBX) protein functions in multiple regulatory roles, including transcriptional activation through its interaction with transcription factors, such as AP-1, ATF/ CREB, NF-kB and Egr-1 without direct binding to DNA. 18, 19 Furthermore, the interaction between HBX and p53 inhibits p53 function in DNA repair and apoptosis. 20 Recent studies have shown that HBX protein modulates the expression of PTEN through downregulation of p53-mediated transcription of PTEN. 21 In addition, HBX regulatory protein turns on multiple signaling pathways in the cytoplasm. Cell signal-transduction pathways that are activated by HBX include Jak1/Stat3 and PI-3 kinase pathways. 22, 23 HBX protein also mediates the activation of Ras-GTP formation and stimulates the Ras/Raf/MAPK signaling cascade, 24, 25 leading to NF-kB activation. 25 Activation of Raf/MEKK1 signaling due to HBX is essential for HBV gene expression. 26, 27 Here, we want to explore whether reovirus, considered as a potential cancer therapeutic agent, might be applicable to HBV-associated hepatocarcinoma cells, and specifically to examine whether the expression of HBX protein might modulate reoviral activity. We report that HBX expression confers resistance to reovirus because of a reduction in DR5 expression and Stat1 activation. We thus propose that HBX expression mimics type I interferon (IFN) signaling, leading to the establishment of an antiviral state that can override the ability of Ras to facilitate reovirus replication, thereby posing potential limits to the use of reovirus as a cancer therapeutic agent in cases where proteins from other viruses may interfere.
Materials and methods

Cell cultures and virus amplification
Chang cells stably expressing vector (Chang-vec), Chang cells stably expressing HBX (Chang-HBX) and murine L929 cells were cultured in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum and 1% penicillin and streptomycin. The Dearing strain of reovirus serotype 3 was purchased from the American Type Culture Collection (ATCC) (Manassas, VA) and propagated in L929 cells. The virus was purified as described elsewhere 28 and viral titer was measured in plaque-forming units (PFUs).
Reagents and antibodies
To inhibit the activation of PI-3 kinases, wortmannin was purchased from Calbiochem (San Diego, CA) and added to cells at different concentrations for 12 or 24 h. For immunoblotting, anti-caspase 3, caspase 8, PARP, DR4, Ras, PKR, Stat1, phospho-Stat1 and b-tubulin antibodies were obtained from Santa Cruz Biotech (Santa Cruz, CA). Akt and its phospho-specific antibody were acquired from Cell Signaling Biotech (Danvers, MA). Anti-phospho-PKR was obtained from Invitrogen (Carlsbad, CA) and glutathione S-transferase (GST)-Raf-RBD fusion protein was obtained from Cytoskeleton (Denver, CO). Anti-DR4 and DR5 antibodies were purchased from Biolegend (San Diego, CA). Polyclonal anti-reovirus antibody as described earlier 1 was used for the detection of l, m and s reoviral proteins.
siRNA transfection Cells were trypsinized and incubated overnight to achieve 60-70% confluency before siRNA transfection. Stat1 siRNA (60 nM, 5 0 -AACTAGTGGAGTGGAAGCGGA-3 0 as sense and 5 0 -AAGGGTCGAGAGAGAGCTGTA-3 0 as anti-sense; Bioneer, Daejeon, Korea) described elsewhere 29 or control siRNA 30 was mixed with Lipofectamine 2000 (Invitrogen). The cells were incubated with the transfection mixture for 6 h and then rinsed with Dulbecco's modified Eagle's medium containing 10% serum. The cells were incubated for 24 h before harvest.
Western blotting assays
Cells were harvested and lysed with lysis buffer (150 mM NaCl, 1% NP-40, 50 mM Tris-HCl (pH 7.5)) containing 0.1 mM Na 2 VO 3 , 1mM NaF and protease inhibitors (Sigma, St Louis, MO). For immunoblotting, proteins from whole-cell lysates were resolved by 10 or 12% SDSpolyacrylamide gel electrophoresis and then transferred to nitrocellulose membranes. Primary antibodies were used at 1:1000 or 1:2000 dilutions, and secondary antibodies conjugated with horseradish peroxidase were used at 1:2000 dilutions in 5% non-fat dry milk. After final washing, nitrocellulose membranes were exposed for an enhanced chemiluminescence assay using the LAS 3000 (Fuji, Tokyo, Japan).
Active Ras capture assays
To capture GTP-bound Ras from cell lysates, a GST-Raf-RBD fusion protein was used as described elsewhere. 31 The cells were lysed with lysis buffer and supernatants were incubated with glutathione-agarose on ice for 30 min to exclude nonspecific binding. After centrifugation, the supernatant was harvested, followed by adding GST-Raf-RBD (Cytoskeleton). The solution was incubated on ice for 1 h followed by adding glutathione-agarose to capture active Ras, which can bind to GST-Raf-RBD. After washing three times, the pellet was mixed with 40 ml of 2 Â SDS loading buffer. To detect the captured Ras, immunoblotting was performed with anti-Ras antibody. 
IFN-b ELISA assays
After virus infection, the cell supernatants were harvested at different time points and used for the measurement of IFN-b production using a detection kit (R&D Systems, Minneapolis, MN). The protocol for the measurement of IFN-b was as recommended by the manufacturer.
Results
HBX expression causes resistance to reovirus-induced apoptotic cell death
As it has been reported that reovirus preferentially replicates in Ras-activated cancer cell lines, 7, 32 and HBX protein in HBV-infected cells induces the activation of Ras, 19, 33 we decided to test whether reovirus might be useful in the treatment of liver cancer cells associated with HBV. For this study, we used Chang liver cells stably expressing either a vector only (Chang-vec) We also examined the levels of reoviral protein during the course of reoviral infection. We found that reoviral proteins were synthesized in both Chang-vec cells and Chang-HBX cells, though at higher levels in the former (Figure 2 ). Chang-HBX cells were still healthy at 72 h post-infection despite carrying a significant load of reoviral proteins (Figures 1a and 2 ).
HBX expression induces the activation of Ras and PKR inactivation Activation of Ras has been reported to enhance the preferential replication of reovirus in cancer cells. 9 Other studies have shown that the HBX protein of HBV augments Ras/Raf/MAPK signal transduction, which contributes to cell proliferation and survival. 34 From this evidence, we expected that Chang-HBX cells should harbor more active Ras protein when compared with Chang-vec cells. When we compared Ras expression in cell lysates from the two cell lines, we found that Ras protein is increased somewhat in abundance in Chang-HBX cells compared with that of Chang-vec cells (Figure 3a) . Consistent with this, the level of active GTP-bound Ras protein, as detected in both cell lines by binding to GST-Raf-RBD fusion protein, was also much higher in Chang-HBX cells than in Chang-vec cells (Figure 3a ). It has also been shown that depletion or inhibition of double-stranded RNA-activated protein kinase (PKR, which normally helps to protect cells from viral replication) allows a dramatic enhancement in reoviral protein synthesis, 7 and we therefore examined PKR status in both cell lines during reovirus infection. We observed that reovirus infection induced upregulation of both PKR abundance and phosphorylation in Changvec cells but not in Chang-HBX cells (Figure 3b ). It appears that HBX-mediated Ras activation is associated with reduced phosphorylation of PKR (Figure 3b) , as suggested earlier.
7,9 Thus, we have the paradoxical result that although inhibition of PKR activity as observed in Chang-HBX cells should normally be expected to enhance reoviral protein synthesis, we instead found higher levels of reoviral proteins in Chang-vec rather than in Chang-HBX cells (Figure 2) . Thus, differential survival in response to reoviral infection in Chang-vec and Chang-HBX cells must be achieved in this case through a different pathway.
HBX protein confers resistance to TRAIL by reducing DR5 in Chang-HBX cells It was reported earlier that the TRAIL signaling pathway, which leads to activation of the death receptor (DR), is associated with reovirus-induced apoptotic cell death. 35 We therefore wished to examine whether the two Chang cell lines might display a differential sensitivity to TRAIL depending on the expression or activity of DR. When Chang-vec and Chang-HBX cells were treated with TRAIL, we observed that Chang-vec cells are very sensitive, whereas Chang-HBX cells are highly resistant to TRAIL (Figure 4a) . At 4 h post-treatment, 80-90% of Chang-vec cells were killed but Chang-HBX cells still survived (Figure 4a) . Consistent with this, we detected cleavage of caspase 8 and PARP from 4 to 8 h post-treatment in Chang-vec cells, but caspase 8 and cleaved PARP protein were not detected in Chang-HBX cells (Figure 4b ). In addition, DR5 was more abundant in the cell lysates of Chang-vec cells and on the cell surface of Chang-vec compared with Chang-HBX (Figures 4b and c) , suggesting that HBX expression reduces DR5 protein levels, thereby lowering sensitivity to TRAIL. We also examined the expression of DR4 protein (which is also responsive to TRAIL), but found undetectable levels in cell lysates or on the cell surfaces of Chang-vec or Chang-HBX (Figures 4b and c) . In addition, we found that DR5 expression is increased at 48 h post-infection in Chang-vec cells, whereas it is not significantly changed in Chang-HBX cells (Figure 4d ). These results suggest that reduced expression of DR5 on the Chang-HBX cells may contribute to their relative resistance to reovirus-induced apoptosis.
HBX expression confers resistance to reovirus in Chang cells by imitating type I IFN signaling On the basis of other studies demonstrating that HBX induces the activation of Jak1 36 and our observation that HBX promotes Chang cell resistance to reovirus ( Figure 1 ), we speculated that HBX might facilitate the activation of Stat1, leading to the establishment of an antiviral state. We therefore examined the activation of Stat1, involved in type I IFN signaling, with the antiphosphoTyr 701 Stat1 antibody, and detected strong phosphorylation of Stat1 in Chang-HBX but weak phosphorylation in Chang-vec cells (Figure 5a ). In addition, according to previous studies demonstrating that PI-3 kinase and Akt kinase are activated by HBX, 37 and reports that PI-3 kinase and Akt kinase are activated during type I IFN signaling, [38] [39] [40] [41] we speculated that PI-3 kinase/AKT signaling may modulate Stat1 signaling in the presence of HBX. To test this issue, we treated both cell lines with wortmannin, an inhibitor of PI-3 kinase and examined whether the activation of Stat1 induced by HBX is inhibited by the suppression of PI-3 kinase activity. We found that wortmannin inhibits the activation of Akt in Chang-vec as expected, and also reduced Akt activity in Chang-HBX cells (Figure 5a ), even though basal phosphorylation levels of both Akt and Stat1 were greater in the cells expressing HBX. However, wortmannin treatment did not cause a significant reduction of phospho-Stat1 in Chang-HBX (Figure 5a ), suggesting that PI-3 kinase/Akt is not directly involved in Stat1 signaling during HBX expression. Next, we investigated whether the activation of Stat1 mediated by HBX transduces a signal, culminating in the enhancement of antiviral transcriptional activity through the ISRE or GAS. As shown in Figure 5b , ISRE-and GAS-mediated transcriptional activity were not detected in Chang-vec cells, whereas ISRE-and GAS-mediated transcriptional activity show five-and eightfold increases, respectively, compared with that of Chang-vec or mock-treated Chang-HBX. The result strongly suggests that phosphorylated Stat1 induced by HBX is guided to target sequences such as ISRE and GAS, leading to antiviral gene expression. On the other hand, when we examined the status of Stat1 during reovirus infection, we noticed that Chang-vec cells exhibit a very mild increase in Stat1 phosphorylation at 48 h post-infection, but Chang-HBX cells keep the enhanced phosphorylation of Stat1 from 0 to 72 h (Figure 5c ). Finally, when we examined the production of IFN-b in the culture supernatants from both cell lines after reovirus infection, an enhanced production of IFN-b was found in the supernatants from Chang-HBX cells infected with reovirus at 48 and 72 h post-infection compared with that in Chang-vec cells. Taken together, the results imply that HBX expression induces antiviral effects that diminish reoviral activity through Stat1 in the cell, which mimics the IFN signaling pathway. We therefore propose that an HBX-mediated antiviral state, through activation of Stat1, can override the normally stimulatory effect of Ras on reoviral replication.
Downregulation of Stat1 with its siRNA blocks reoviral resistance in Chang-HBX cells
To confirm that Stat1 activation due to HBX expression confers resistance to reovirus infection, we suppressed Stat1 expression with its siRNA and treated Chang-HBX cells with reovirus. We then measured cellular susceptibility to reovirus in cells treated with stat or control siRNA and whether IFN-b production from cells treated with Stat1 siRNA was decreased compared with cells treated with control siRNA. As shown in Figure 6a , we optimized conditions for the suppression of Stat1 with its siRNA and confirmed the reduced expression of Stat1. Under this condition, Chang-HBX cells treated with Stat1 siRNA were susceptible to reovirus infection, resulting in approximately 40% reduction of cell number compared to that of the cells treated with control siRNA (Figure 6b ). Reovirus did not affect the viability of Chang-HBX cells treated with control siRNA (Figure 6b ). In addition, we found that IFN-b production from the supernatant of Chang-HBX cells treated with Stat1 siRNA is reduced compared with that of cells treated with control siRNA at 72 h post-infection (Figure 6c) . Accordingly, we propose that Stat1 activation mediated by HBX stimulates the formation of an antiviral state, leading to resistance to reovirus infection.
Discussion
Although we initiated this study to explore the potential application of reovirus to hepatocellular carcinoma, which has not been attempted yet by other groups, we obtained many unexpected results that reveal potential new functions of HBX, including the inhibition of DR5 expression and antiviral activity through Stat1, plus inhibition of reoviral oncolysis.
HBV infection afflicts more than 400 million people worldwide and accelerates the development of hepatocellular carcinoma. 42 Among HBV gene products, HBX has been implicated in multiple signaling pathways leading to liver carcinogenesis. 43 However, an oncogenic role for HBX has been controversial as HBX expression sensitizes or sometimes prevents ligand-induced cell death in different models. Another study earlier reported that HBX can induce an increase in DR4 expression, leading to sensitization to TRAIL-induced apoptotic cell death of hepatocytes. 15 Additionally, HBX expression enhances TNF-a-induced death of liver cells. 44 However, a different study has shown that HBX inhibits Fas-mediated apoptosis through upregulation of the SAPK/JNK pathway. 45 Herein, our study reveals that HBX protein reduces DR5 expression, in contrast to previous studies, 15, 44 by mechanisms that remain unresolved. Furthermore, we found that caspase 8 and PARP protein themselves were not detected in Chang-HBX cells, supporting resistance to virus-induced cytotoxicity. We are currently investigating whether HBX actually causes a reduction in the synthesis of caspase 8 and PARP. In addition, we observed that there is no difference in the expression of junctional adhesion molecule (JAM)-A, known as a primary receptor of reovirus 46, 47 on the surfaces of Chang-vec and Chang-HBX cells (data not shown), thereby excluding the possibility that the enhanced susceptibility of Chang-vec to reovirus may be attributed to overexpression of JAM-A on the surface of Chang-vec compared with Chang-HBX cells.
We now report that HBX possesses an additional antiviral function, which is to mimic type I IFN signaling. Previous studies have shown that HBX expression activates Jak1, but not Jak2 or Tyk2, through specific interactions with Jak1, 36 resulting in constitutive tyrosine phosphorylation of Stat3 and Stat5 without direct physical interaction. 36 Additionally, an HBX mutant that does not target mitochondria fails to induce phosphorylation of Stat3, suggesting an important role of HBX localization at mitochondria. 22 Several reports have attempted to connect HBX to the enhancement of Stat3 transcriptional activity because aberrant expression of Stat3 is closely related to cellular transformation. [48] [49] [50] Here, because we observe that HBX activates Stat1 (which might be mediated by Jak1), we suggest that HBX expression itself may be enough to constitutively transduce an intracellular signal of type I IFN without an interaction of type I IFN with its receptor at the cell surface, and thus the HBX oncoprotein causes an adventitious stimulation of the type I IFN signaling pathway. The HBX-induced signaling does not exactly match type I IFN-mediated signaling because we found that wortmannin does not inhibit phosphorylation of Stat1 during HBX expression, and the potential biological consequences of HBX-induced antiviral activity in hepatocytes will require further investigation.
It is also of interest to consider the proposed role of PKR in the protection against reovirus infection, which has been controversial. Early studies showed that activated PKR phosphorylates eukaryotic initiation factor-2a (eIF-2a), leading to the reduction of host cell protein translation and the induction of IFN-b production, eventually culminating in an antiviral status. 50, 51 Inhibition of PKR phosphorylation by 2-aminopurine results in a drastic increase of reoviral protein synthesis in untransformed cells, 52 and loss of PKR triggers more severe virulence in murine myocarditis. 53 However, further studies have reported that the growth of reovirus is unaffected by PKR knockdown in HeLa cells 54 and PKR activation alone is not sufficient to elicit antiviral effects on reovirus growth in mouse embryonic fibroblasts. 55 Thus, other host factors besides PKR must also be important in conferring an anti-reoviral response. Here, we report that Ras-mediated inhibition of PKR activity does not provide a preferential environment for reovirus growth in Chang-HBX cells. Instead, we find that a Stat1-mediated antiviral status restricts reovirus replication in Chang-HBX cells. Furthermore, the reduced expression of Stat1 by its siRNA converts resistance to reovirus into susceptibility in Chang-HBX cells, confirming that Stat1 activation due to HBX plays a crucial role in the resistance to reovirus infection. We are now undertaking further studies to determine how HBX expression activates Stat1, leading to the increase in antiviral transcriptional activity through ISRE and GAS elements in Chang-HBX cells. Importantly, our results suggest that reovirus therapy in HBV-infected liver carcinoma cells may be ineffective due to this blockade, even though Ras is activated in the host cells, unless strategies to overcome the HBX inhibition can be developed.
